Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kelly

Showing results (91-100 of 253) with videos related to

Pageof 26
Sort By:
Journal of Geriatric Oncology|May 4, 2024
The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based studyNikita Nikita, Krupa Gandhi, Scott W Keith, et al.
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
Cancer Letters|January 18, 2011
Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancerSun Jung Kim, William Kevin Kelly, Alan Fu, et al.
Urology|December 12, 2002
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustineMichael J Morris, Jean Santamauro, Jinru Shia, et al.
Cancer|November 8, 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811William Kevin Kelly, Susan Halabi, Aymen Elfiky, et al.
Clinical Lung Cancer|March 4, 2006
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acidLee M Krug, Tracy Curley, Lawrence Schwartz, et al.
Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.
Urology|February 1, 2003
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trialDavid Andrew Verbel, W Kevin Kelly, Oren Smaletz, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2016
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasmaJia Li, Harriet Kluger, Lesley Devine, et al.
Clinical Genitourinary Cancer|October 10, 2009
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancerSusan F Slovin, W Kevin Kelly, Andrew Wilton, et al.
Pageof 26

Showing results (91-100 of 253) with videos related to

Sort By:
Pageof 26
Journal of Geriatric Oncology|May 4, 2024
The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based studyNikita Nikita, Krupa Gandhi, Scott W Keith, et al.
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
Cancer Letters|January 18, 2011
Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancerSun Jung Kim, William Kevin Kelly, Alan Fu, et al.
Urology|December 12, 2002
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustineMichael J Morris, Jean Santamauro, Jinru Shia, et al.
Cancer|November 8, 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811William Kevin Kelly, Susan Halabi, Aymen Elfiky, et al.
Clinical Lung Cancer|March 4, 2006
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acidLee M Krug, Tracy Curley, Lawrence Schwartz, et al.
Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.
Urology|February 1, 2003
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trialDavid Andrew Verbel, W Kevin Kelly, Oren Smaletz, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2016
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasmaJia Li, Harriet Kluger, Lesley Devine, et al.
Clinical Genitourinary Cancer|October 10, 2009
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancerSusan F Slovin, W Kevin Kelly, Andrew Wilton, et al.
Pageof 26